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Abstract Thrombin-induced extracellular signal-regulated ki-
nase 2 (ERK2) activation is negatively regulated in conditions of
KllbL3 integrin engagement and platelet aggregation. Here we
show by Western blotting with antibodies against mono- and
biphosphorylated forms of ERK2 that the dephosphorylation of
ERK2 by KllbL3 engagement affects threonine183 and not
tyrosine185. Addition of a potent serine/threonine phosphatase
inhibitor, okadaic acid (OA), restored thrombin-induced threo-
nine phosphorylation of ERK2 in conditions of platelet aggrega-
tion, whereas OA had no effect in the absence of KllbL3
engagement. These observations are consistent with KllbL3
engagement acting via at least one serine/threonine phosphatase,
which dephosphorylates the phosphothreonine183 residue of
ERK2. Moreover, a small amount (14%) of ERK2 was
translocated to the KllbL3-dependent cytoskeleton, mostly in
a monophosphorylated (i.e. inactive) form, suggesting that
cytoskeleton-associated ERK2 plays only a minor role, if any.
Finally, we show that negative regulation (i.e. dephosphorylation)
occurs primarily or totally in the cytosol and that the KllbL3-
dependent ERK2 Thr183-specific phosphatase is different from
phosphatase 1 (PP1) or PP2A. We conclude that KllbL3
engagement down-regulates ERK2 through selective dephos-
phorylation of the phosphothreonine183 residue by a cytosolic
serine/threonine phosphatase different from known platelet
phosphatases. 0 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The mitogen-activated protein kinase (MAPK) family com-
prises extracellular signal-regulated kinase (ERK), c-Jun-
NH2-terminal kinase (JNK) and p38 MAPK. The activation
of MAPKs requires phosphorylation of the threonine and ty-
rosine residues located within the TXY motif of kinase do-
main VIII [1]. The phosphorylation of both the Thr183 and
Tyr185 residues of ERK2 is catalyzed by dual-speci¢c up-
stream MAPK kinases, MEK1 or MEK2 [2]. The regulation
of ERK2 activity involves several types of phosphatases that
dephosphorylate both threonine and tyrosine activating resi-
dues. The dual-speci¢c threonine/tyrosine phosphatase family,
also called the MAPK phosphatase family, includes MKP-1,
PAC-1, MKP-3 or MKP-4. The members of this family in-
activate ERK, the pattern of inactivation depending on cell
type and the cytosolic or nuclear location [3]. MKP-3 and
MKP-4 have been shown to be more speci¢c for ERK than
JNKs and p38 MAPKs [4^5]. MKP-3 substrate selectivity
appears to depend primarily on the N-terminal-speci¢c region
of the phosphatase and then on substrate recognition domains
within ERK [6^7]. Serine/threonine phosphatase 1 (PP1) and
PP2A have been also shown to inhibit the activity of the
ERK1/2 pathway by the dephosphorylation of MEK1/2 and
EKR1/2. PP2A is involved in regulation of ERK2 pathway
induced by inhibitory concentrations of epidermal growth fac-
tor (EGF) in A431 cell lines [8]. PP2A has also been shown to
dephosphorylate the Thr183 residue of ERK2 directly in PC12
cells [9]. Nevertheless, MEK1 and MEK2 activities may also
be regulated by the activation of PP1 and PP2A [10].
Although the SH2 domain-containing tyrosine phosphatases
(SHP1 and SHP2) have been found to regulate MAPK path-
ways positively or negatively [11^13] one tyrosine phosphatase
family, comprising STEP, PTP-SL and He-PTP, has been
shown to interact with and to dephosphorylate the Tyr185
residue of ERK2 [14^16].
In platelets, all three families of MAPKs are activated by
physiologic agonists including thrombin [17] and collagen [18].
Thrombin-induced ERK2 activation is mediated by MEK1/2
and is dependent on both calcium and conventional protein
kinase C. However, the regulation of MAPKs by phospha-
tases has not been investigated in these nucleus-free cells.
Protein phosphatase activities in platelets seem to play an
important role in regulating signaling events and conse-
quently, platelet activation and aggregation. For example,
the incubation of platelets with okadaic acid (OA), a potent
inhibitor of PP1 and PP2A, results in the inhibition of acti-
vated-platelet functions [19], calcium mobilization and phos-
phoinositide production [20]. These serine/threonine phospha-
tases may also be involved in cytoskeletal reorganization, as
they are translocated in this platelet fraction during thrombin-
induced aggregation [21^22]. At least three non-receptor tyro-
sine phosphatases are expressed in platelets, and two of these
phosphatases are PTP-1B and SHP2. These enzymes are acti-
vated upon thrombin-induced platelet activation and KllbL3
engagement [23]. The calcium-dependent enzyme calpain
cleaves PTP-1B after integrin engagement, thereby activating
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the phosphatase [24]. Moreover both SHP-1 and SHP-2 phos-
phatases appear to be phosphorylated in thrombin-induced
activated platelets and to associate with several Src-family
tyrosine kinases and the adhesion molecule PECAM-1 [25^
28].
We have previously shown that, in human platelets, the
thrombin-mediated activation of ERK2 and JNK1 is nega-
tively regulated by KllbL3 engagement in platelet aggregation
[29^30]. These were the ¢rst reports showing that an integrin
could down-regulate MAPKs. In this study, we investigated
the mechanism involved in ERK2 down-regulation and the
possible role of phosphatases.
We found that the down-regulation of ERK2 activity upon
KllbL3 engagement was directly correlated with dephosphor-
ylation of the Thr183 residue, but not of the Tyr185 residue.
Thrombin-induced platelet activation in the presence of the
serine/threonine phosphatase inhibitor OA increased ERK2
activation in conditions of integrin engagement, providing
further evidence for the involvement of a serine/threonine
phosphatase. Finally, the small proportion of ERK2 translo-
cated to the cytoskeleton (CSK) suggest that KllbL3-depen-
dent negative regulation occurs in the cytosol.
2. Materials and methods
2.1. Reagents
Bovine K-thrombin, the synthetic peptide Arg-Gly-Asp-Ser
(RGDS), leupeptin and aprotinin were purchased from Sigma (St.
Louis, MO, USA). PD98059 was obtained from Biomol (Plymouth
Meeting, PA, USA). Rabbit polyclonal antibodies directed against the
C-terminal peptides of ERK1/2 (C-14), rabbit polyclonal antibody
directed against the phosphorylated forms of ERKs (ERKs-P) and
the phosphothreonine form of ERKs were obtained from Promega
(Madison, WI, USA). Mouse monoclonal antibody directed against
the phosphotyrosine of ERKs was obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Donkey anti-rabbit and anti-mouse
horseradish peroxidase-conjugated IgG were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA, USA).
2.2. Platelet preparation and aggregation
Platelets are isolated as previously described [29]. Platelet aggrega-
tion was then initiated by adding bovine thrombin (1 NIH/ml), with
constant stirring (1200 rpm) in an aggregometer cuvette (Chronolog
dual-beam aggregometer). Aggregation was measured and expressed
as a percent change in light transmission, with the blank sample (bu¡-
er without platelets) de¢ned as having 100% transmission.
2.3. Immunoblotting
Samples were subjected to immunoblotting as previously described
[29,30]. Brie£y, platelet lysates were obtained by adding SDS denatur-
ing bu¡er (50 mM Tris, 100 mM NaCl, 50 mM NaF, 5 mM EDTA,
40 mM L-glycerophosphate, 100 mM phenylarsine oxide, 5 Wg/ml
leupeptin, 5 Wg/ml aprotinin, SDS 10%, pH 7.4) to the sample and
heating at 95‡C for 5 min. Nitrocellulose membranes were treated
with polyclonal anti-ERKs antibody (1:20 000), anti-ERKs-P anti-
body (1:10 000), anti-phosphotyrosine form of ERKs antibody
(1:10 000) or the anti-phosphothreonine form of ERKs antibody
(1:10 000) and then with either horseradish peroxidase-conjugated
goat anti-rabbit IgG (1:20 000) or with peroxidase-conjugated rabbit
Fig. 1. Regulation of ERK2 by KllbL3 engagement. Washed platelets were preincubated in the presence (gray bars) or absence (white bars) of
RGDS peptide (1 mM) and stimulated with thrombin (1 NIH/ml) at various times. Platelets were solubilized and analyzed by SDS^PAGE fol-
lowed by Western blotting, using polyclonal antibodies recognizing the phosphotyrosine and phosphothreonine residues of ERKs (ERK-YPTP)
(A, E), phosphotyrosine (ERK-YP) (B, F), or phosphothreonine (ERK-TP) (C, G) residues only. Results are representative of ¢ve experiments.
ERK2 phosphorylation was measured by densitometry analysis in the presence of absence of RGDS peptide and the results were normalized
with respect to platelets treated with thrombin alone (2 min), expressed as a relative intensity.
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anti-mouse IgG (1:20 000). Immunoreactive bands were visualized
with enhanced chemiluminescence detection reagents (Pierce).
2.4. CSK extraction
Brie£y, we isolated the CSK of control or activated platelet suspen-
sions by adding 0.4 ml of ice-cold CSK bu¡er (100 mM Tris^HCl, 2%
Triton, 50 mM NaF, 150 mM L-glycerophosphate, 5 mM EDTA,
2 mM orthovanadate, 5 Wg/ml leupeptin, 10 Wg/ml aprotinin, pH
7.5). After 30 min of incubation at 4‡C, Triton X-100-soluble and -
insoluble fractions were separated by centrifugation at 12 000Ug for
15 min at 4‡C. Total CSK, corresponding to the Triton X-100-insolu-
ble fraction, and equal amounts of samples from total lysates and the
Triton X-100-soluble fraction were subjected to 12% SDS^polyacryl-
amide gel electrophoresis (PAGE). Western blotting was performed
with an antibody recognizing total ERK2 (ERK2-P, ERK2) or vari-
ous forms of phosphorylated ERK2: T183-phosphorylated ERK2
(ERK2-TP, and ERK2-TPYP) or Y185-phosphorylated ERK2
(ERK2-YP and ERK2-TPYP).
3. Results
3.1. Negative ERK2 regulation by KllbL3 integrin involves
dephosphorylation of the phosphothreonine183 residue
As KllbL3 engagement down-regulates ERK2 activity [29^
30] it must decrease the phosphorylation of either T183 and
Y185, or both. This raised the question as to which step in the
ERK2 activation pathway was the target of KllbL3. We there-
fore compared the phosphorylation states of the tyrosine185
and threonine183 residues of ERK2 after thrombin induction,
in the presence or absence of RGDS peptide (i.e. with and
without aggregation), by Western blotting using antibodies
speci¢c for ERK2 with phosphorylated threonine residues,
tyrosine residues, or both. As previously reported, ERK2
phosphorylation levels were 10 times higher in the presence
of RGDS peptide than in its absence after 2 min of thrombin
induction, as shown by Western blotting with the dual phos-
phorylation antibody (ERK2-TPYP) (Fig. 1A,E). As various
phosphatases present in platelets have been reported to be
activated upon thrombin-induced platelet activation and
KllbL3 engagement [23], we suggested that RGDS peptide
blocked the KllbL3-dependent dephosphorylation of ERK2
by phosphatase. A similar up-regulation of phosphorylated
ERK2 (increase by a factor of 11) was observed in the pres-
ence of RGDS peptide with the T183P-speci¢c antibody (Fig.
1B,F). In contrast, no signi¢cant change in the tyrosine phos-
phorylation of ERK2 was observed, in the presence or ab-
sence of RGDS peptide, in Western blots with the Y185P-spe-
ci¢c antibody (Fig. 1C,G). A non-speci¢c band detected
throughout corresponded to a cross-reaction with JNK1. In
conclusion, our data show that only the phosphothreonine
residue was negatively regulated by KllbL3 engagement.
3.2. A threonine phosphatase dependent on KllbL3 engagement
decreases ERK2 activation
Speci¢c dephosphorylation of T183 but not of Y185 strongly
suggests the involvement of a serine/threonine phosphatase.
We thus investigated the e¡ect of OA, an inhibitor of ser-
ine/threonine phosphatases PP1 and PP2A, on ERK2 phos-
phorylation. In conditions of platelet aggregation, a dose-de-
pendent increase in ERK2 activity was observed in the
presence of various concentrations of OA (0^200 nM), with
activity reaching 534%Q144% (P6 0.05) at a concentration
of 200 nM (Fig. 2A,E). Moreover, using an anti-T183P anti-
body, we showed that OA increased ERK2 phosphorylation
by 400Q 133% (P6 0.05) at OA concentrations of 200 nM
Fig. 2. E¡ect of a serine/threonine phosphatase inhibitor (OA) on ERK2 activation. Washed platelets were stimulated with thrombin (2 min)
and various concentrations of OA (0^200 nM) in the presence or absence of RGDS peptide. Platelet lysates were analyzed by Western blotting,
using polyclonal antibodies recognizing the phosphotyrosine and phosphothreonine residues of ERKs (ERK-YPTP) (A, E, F) (gray bars), phos-
photyrosine (ERK-YP) (C, E, F) (white bars) and phosphothreonine residues (ERK-TP) (B, E, F) (black bars). Results are representative of
four experiments. ERK2 phosphorylation was measured by densitometry analysis in the presence (F) or absence (E) of RGDS peptide and the
results were normalized with respect to platelets treated with thrombin alone (2 min), expressed as a relative intensity.
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(Fig. 2B,E). In contrast, in the presence of RGDS peptide, in
conditions in which KllbL3 was not engaged, no statistically
signi¢cant variation in ERK2 activity or in levels of the phos-
phothreonine form of ERK2 (even at 200 nM OA) was ob-
served (Fig. 2A,B,F). Thus, the threonine phosphorylation of
ERK2 was negatively regulated by KllbL3 engagement and a
serine/threonine phosphatase was involved in this negative
regulation. The incomplete restoration of T183 phosphoryla-
tion in the presence of OA (increase in phosphorylation by a
factor of ¢ve) whereas RGDS peptide increased the level of
phosphorylation by a factor of 10, may be accounted for by
the use of only a low concentration of OA (200 nM), to
prevent the inhibition of platelet aggregation. Surprisingly,
increasing the concentration of OA decreased the level of
phosphorylation of the Y185 residue of ERK2 (halved at 200
nM OA) in the presence or absence of RGDS peptide (Fig.
2C,E,F). Our data suggest that a serine/threonine phosphatase
is also involved in thrombin-induced ERK2 phosphorylation,
independent of KllbL3 engagement and increasing the amount
of the phosphotyrosine form of ERK2. Nevertheless, ERK2
activity is negatively regulated by serine/threonine phospha-
tases in conditions of platelet aggregation.
3.3. Subcellular localization of activated ERK2 and regulation
3.3.1. Some ERK2 is translocated to the CSK after thrombin
induction. As KllbL3 engagement induces the reorganization
of the actin CSK and the translocation of a number of signal-
ing molecules, we assessed the extent to which the phosphor-
ylated and unphosphorylated forms of ERK2 were associated
with the CSK. We fractionated the total lysate into Triton
X-100-soluble and -insoluble (corresponding to CSK) frac-
tions. To optimize sensitivity, total CSK from 800 Wl of plate-
let suspension was subjected to Western blotting whereas only
a fraction (50 Wl of 800 Wl) of total lysate and the Triton
X-100-soluble fraction was analyzed. Comparison of total
ERK2 (ERK2 and ERK2-P) levels in whole lysate, deter-
gent-soluble fraction and CSK showed that ERK2 and
ERK2-P (ERK2-YPTP, ERK2-YP, ERK2-TP) were present
in the detergent-soluble fraction and the CSK (Fig. 3A^D).
Quantitative analysis showed that in resting platelets,
6.2 Q 1.1% of total ERK2 was detectable in the CSK (Fig.
4A,B). This level increased to 14.0 Q 3.5% after 3 min of
thrombin induction, showing that only a small amount of
ERK2 was translocated. Moreover, CSK-associated ERK2
was mostly un- or dephosphorylated (Fig. 3A,D). These re-
sults are consistent with two hypotheses: (1) translocation of
ERK2 into the CSK occurs independently from the state of
ERK2 phosphorylation; (2) ERK2-P is the species of ERK2
translocated, but is rapidly dephosphorylated in the CSK. As
the amount of ERK2 in the CSK is not a¡ected by PD98059,
a MEK1/2 inhibitor (i.e. in conditions of ERK2 inactivation;
Fig. 5), we conclude that ERK2 translocation to the CSK is
independent of activation state, and therefore also of phos-
phorylation state. Finally, comparison of ERK2-YPTP,
ERK2-YP, and ERK2-TP levels (Fig. 3B^D), suggests that
ERK2 is rapidly activated (30 s after the addition of throm-
bin) and that a serine/threonine phosphatase acts as soon as
30 s to 1 min after thrombin induction.
Thus, our results show that only small amounts of ERK2
are translocated to the CSK, in an unphosphorylated and
monophosphorylated inactive form, and that the active sub-
strates of ERK2 are in the cytosol.
3.3.2. ERK2 is negatively regulated in the Triton X-100-
soluble fraction after KllbL3 engagement. We compared the
subcellular location and activation of ERK2 in the presence
and absence of RGDS peptide. ERK2 and ERK2-P were
detected in both compartments in the absence of RGDS pep-
tide (Fig. 6A,B). Similar increases in ERK2-P levels were ob-
served in the presence of RGDS peptide in the soluble frac-
tion and in total lysate after thrombin induction, suggesting
that T183 dephosphorylation occurred in the cytosol (results
Fig. 3. Distribution of ERK2 after thrombin activation. Washed
platelets were stimulated by thrombin (1 NIH/ml) for various
lengths of time with stirring. Platelets were solubilized in Triton
X-100 as described in Section 2. A sample (50 Wl) of whole lysate
and of Triton X-100-soluble fraction (in contrasts to the total Triton
X-100 insoluble fraction), corresponding to the CSK, were separated
by SDS^PAGE followed by Western blotting using (A) an anti-total
ERK2 antibody (ERK2-P, ERK2), (B) an anti-ERK2-YPTP, (C)
(ERK2-YP) or (D) (ERK2-TP). Results are representative of four
experiments.
Fig. 4. Translocation of ERK2 in the CSK. Washed platelets were
stimulated by thrombin (1 NIH/ml) in the presence or absence of
PD 98059 (20 WM) for various lengths of time, with stirring. Plate-
lets were solubilized in Triton X-100 as described in Section 2. The
Triton X-100-soluble fraction, corresponding to the CSK, was re-
solved as previously described and Western blotted, using a poly-
clonal antibody recognizing both phosphorylated and non-phosphor-
ylated ERK2 (A^D). Results are representative of three
experiments.
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not shown). In contrast, RGDS peptide decreased the amount
of ERK2 and ERK2-P in the CSK by 73%, con¢rming that
the translocation of ERK2 and ERK2-P depended principally
on the KllbL3-dependent CSK. Finally, our results strongly
suggest that negative regulation by KllbL3 engagement occurs
mainly in the cytosol. The fact that only 14% of ERK2 was
translocated to the CSK suggests that even if negative regu-
lation occurred in the CSK, it played only a minor role in
overall regulation.
In conclusion, our results show that the translocation of
ERK2 to the CSK depends principally on KllbL3 engagement
and that negative regulation occurs mostly or entirely in the
cytosol.
4. Discussion
In this report, we investigated the mechanism leading to
ERK2 down-regulation following KllbL3 engagement [29,30].
We demonstrated that the phosphothreonine183 and phos-
photyrosine185 residues necessary for ERK2 activity were dif-
ferentially regulated in conditions of platelet aggregation. As
previously reported [30], ERK2 activity was up-regulated (by
a factor of 10) in the presence of RGDS peptide, conditions
corresponding to thrombin-induced platelet activation with-
out aggregation. Similar levels of RGDS-induced up-regula-
tion (increase by a factor of 11) were observed for the phos-
phothreonine183 residue, with an antibody directed against
this residue, whereas no signi¢cant change was observed in
levels of the phosphotyrosine185 residue of ERK2. To our
knowledge, this is the ¢rst report showing the di¡erential reg-
ulation by integrin engagement of phosphorylation of the T183
and Y185 residues of ERK2. Moreover, both experiments
showed that this down-regulation involved activation of ser-
ine/threonine phosphatases dependent on KllbL3 integrin en-
gagement that act directly on ERK2. We evaluated the role of
phosphatases in this regulation by investigating the e¡ect of
OA, a potent inhibitor of the serine/threonine phosphatases
PP1 and PP2A. It has been reported that PP2A regulates
ERK2 under conditions of growth inhibition by EGF in
A431 cells [8]. In these conditions, a correlation between
PP2A activity induced by EGF and inhibition of ERK2 ac-
tivity was observed [8]. PP2A has also be shown to be in-
volved in the negative regulation of MAPK activity [9]. In
our model, the addition of OA in conditions of platelet
aggregation up-regulated ERK2 activity and phospho-
threonine183 residue levels whereas no signi¢cant variation
was observed in the absence of ¢brinogen binding, suggesting
that a serine/threonine phosphatase dependent on KllbL3 en-
gagement in platelets was involved. In the presence of OA, the
level of ERK2 activity was not completely restored in the
presence of RGDS peptide. This may be due to the e¡ects
of di¡erent serine/threonine phosphatases acting on ERK2,
one of which was una¡ected by OA. Alternatively, given the
low concentrations used (200 nM), OA may have not com-
pletely inhibited serine/threonine phosphatase activity. The
serine/threonine phosphatases PP2A and PP1, which are in-
hibited by low concentrations of OA (IC50 PP2A: 0.2 nM;
IC50 PP1: 20 nM) may be involved in this T183 dephosphor-
ylation. Surprisingly, in conditions of thrombin-induced plate-
let aggregation, no association of ERK2 with PP2A or PP1
was detected in coimmunoprecipitation experiments, in the
presence or absence of RGDS peptide (results not shown).
This suggests that PP2A and PP1 may not be the phospha-
tases involved in dephosphorylation of the threonine183 resi-
due of ERK2. Alternatively, PP2A and/or PP1 may actually
involved, but the association^dissociation of ERK2 and phos-
phatase may not result in the formation of a complex stable
enough to be detected in our conditions. A direct association
between ERK2 and PP2A was observed only in in vitro ex-
periments based on puri¢ed enzymes (ERK2 and PP2A). It is
possible that our conditions (total cell lysate and IgG-bound
enzymes) hindered the formation of such an association. A
third possibility is that other phosphatases such as PP4 and
PP5, which have been reported to be sensitive to OA [31], may
be involved. Finally, we cannot exclude the possibility of an
unknown serine/threonine phosphatase acting on ERK2.
Fig. 5. Quanti¢cation of ERK2 in the CSK. Washed platelets were
stimulated by thrombin (1 NIH/ml) in the presence or absence of
PD 98059 (20 WM) for various lengths of time, with stirring. Plate-
lets were solubilized in Triton X-100 as described in Section 2. The
Triton X-100-soluble fraction, corresponding to the CSK, was re-
solved as previously described and subjected to Western blotting,
using a polyclonal antibody recognizing both phosphorylated and
non-phosphorylated ERK2. ERK2 was measured by densitometry
analysis and the results are representative of three independent ex-
periments.
Fig. 6. Subcellular localization of the negative regulation of ERK2.
Washed platelets were stimulated with thrombin (1 NIH/ml) for var-
ious lengths of time, with stirring, in the presence or absence of
RGDS peptide (1 mM). Samples were solubilized in Triton X-100
as described in Section 2. A sample (50 Wl) of total lysate and of
the Triton X-100-soluble fraction, corresponding to the CSK, was
separated by SDS^PAGE and Western blotted, using (A) an anti-
ERK2 or (B) an anti-ERK2-YPTP. Results are representative of
three experiments.
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We also observed that OA decreased the level of phosphor-
ylation of Y185. However, this phosphorylation was indepen-
dent of KllbL3 engagement. As changes in pY185 mediated by
OA occurred after thrombin activation, the simplest interpre-
tation is that OA inhibited a serine/threonine phosphatase
involved in the negative regulation of a tyrosine phosphatase.
PTP-1B, which is present in platelets, has been reported to be
phosphorylated on the serine residue responsible for its enzy-
matic activation [32]. Moreover, the treatment of cells with
OA resulted in the serine phosphorylation of PTP-1B and
stimulation of PTP-1B phosphatase activity [33].
ERK2 is known to associate with the CSK [34] and, be-
cause KllbL3 controls the actin CSK, we investigated whether
KllbL3-dependent down-regulation was associated with CSK.
As previously reported [35], we found that ERK2 was present
in both the detergent-soluble fraction and the CSK. Compar-
ison of ERK2-P, in the shift assay, and ERK2-YP and ERK2-
TP in the detergent-soluble fraction and CSK, suggested that
monophosphorylated forms (ERK2-YP and ERK2-TP) of
ERK2 were present in both fractions, whereas only a low level
of biphosphorylated forms (ERK2-YPTP) was present in
CSK. At early time points (30 s and 1 min), only the tyrosine
form of ERK2 was detected, suggesting that ERK2 is acti-
vated after 30 s of thrombin induction and that a serine/threo-
nine phosphatase masks ERK2 activity up to that time point.
Moreover, the small proportion of ERK2 (6%) in resting
platelets increased to 14% after thrombin induction. Maximal
ERK2 translocation was observed at 30 s when ERK2 is still
mostly inactive, which suggests that ERK2 activation is not
required for translocation. This hypothesis was con¢rmed in
conditions in which ERK2 was inhibited by PD 98059, a
MEK1/2 inhibitor, that did not a¡ect the translocation of
unphosphorylated ERK2 to the CSK. Finally, we observed
that cytochalasin D did not a¡ect ERK2-YPTP activity after
thrombin activation, strongly suggesting that actin CSK is not
involved in T183 down-regulation (results not shown).
The fact that 90% of ERK2 translocation was dependent on
KllbL3 engagement does not make it possible to draw de¢ni-
tive conclusions concerning the site at which negative regula-
tion occurs. One possibility is that negative regulation occurs
only in the cytosol (soluble fraction), generating monophos-
phorylated forms of ERK2, which are then translocated from
the cytosol to the CSK. The corollary is that KllbL3 activates
a cytosolic serine/threonine phosphatase. This mechanism
would be analogous to activation of the tyrosine phosphatase
PTP-1B by cleavage by a calcium-dependent protease, calpain,
itself activated by KllbL3 engagement [24]. The other possibil-
ity is that negative regulation occurs mostly in the cytosol, but
with some regulation also occurring in the CSK. In this case,
one would have to postulate the existence of a phosphatase
associated with, or translocated in the KllbL3-dependent CSK.
Only 14% of total ERK2 is present in the CSK, which
strongly suggests that the regulation observed in the cytosol
corresponds to a large part of the regulation that occurs in the
whole platelet. This was con¢rmed by comparing the level of
ERK2-YPTP, equivalent in total lysate and the Triton X-100-
soluble fraction (cytosol), in the presence and absence of
RGDS (results not shown).
In conclusion, our results show that the thrombin-induced
phosphorylation of the threonine183 and tyrosine185 residues
of ERK2 is di¡erentially regulated by KllbL3 integrin engage-
ment. Our data provide evidence that T183 is dephosphorylat-
ed via a serine/threonine phosphatase in conditions of platelet
aggregation and that negative regulation occurs in the cytosol.
This is the ¢rst report showing a dynamic relationship be-
tween integrin engagement and selective dephosphorylation
of ERK2.
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